STOCKHOLM--(BUSINESS WIRE)--Vivolux AB, a drug discovery company specialized in cancer treatment, announced today that data that forms the basis for one of the company's promising projects has been published in the journal Nature Medicine. Researchers at the Karolinska Institute have discovered a novel cancer drug target. A small molecule has been identified that blocks the cellular machinery for breaking down defective proteins, leading to apoptosis – programmed cell death – of tumor cells.
